Pulitzer Prize-winning columnist and author. Read my new book Big Science and my blog at https://t.co/XfRAFQVUlJ mhiltzik@latimes.com

Are most academic papers really worthless? Don't trust this worthless statistic

latimes.com — One of the most eye-catching statistics published during the slow-news period of Thanksgiving week was about academic research. The finding was that the vast majority of articles published in the arts, humanities, and social sciences are never cited by another researcher.

How that CEO who jacked up a drug price by 5,000% is roiling biotech--again

latimes.com — Everyone who follows the drug-pricing controversy already knows the exploits, if not the name, of Martin Shkreli. He's the CEO whose company, Turing Pharmaceuticals, acquired the rights to a drug that's crucial for some HIV and cancer patients and promptly jacked up its price by 5,000%, to $750...

Bringing back Glass-Steagall isn't the panacea you think it is

latimes.com — The Glass-Steagall Act, that Depression-era banking reform that was repealed in 1999 during the financial deregulation craze, has taken on a totemic significance for Wall Street reformers. (Think Elizabeth Warren and Bernie Sanders.)

Are daily fantasy sports contests gambling or games of skill?

latimes.com — If Californians — indeed, all Americans — had a thoughtful, consistent approach to gaming, daily fantasy sports sites such as FanDuel and DraftKings would be treated as gambling and their sponsors regulated and taxed. They'd be subjected to government oversight, background checks of employees, audits of their books and certification that their games aren't rigged — just like most other forms of U.S.

Can Canada show us how to fix income inequality? A talk with Chrystia Freeland

latimes.com — There must be few government ministers anywhere in the Western world better prepared to address issues of economic growth and income inequality than Chrystia Freeland. Now 47, she served as a Moscow bureau chief, Eastern European correspondent, and editor in several capacities at the Financial Time--and many other journalistic posts--before leaving journalism in 2013 to run successfully for a seat in the Canadian parliament.
Nov 20, 2015

RT @latimes: Can Canada show us how to fix income inequality? Columnist @hiltzikm tries to find out lat.ms/1MHx0TE pic.twitter.com/1QkQngcn83

A big insurer is threatening to pull out of Obamacare. What does that mean?

latimes.com — Hyperventilating Keep up to date with the Economy Hub. Follow @hiltzikm on Twitter, see our Facebook page , or email michael.hiltzik@latimes.com .
Nov 25, 2015

Is UHC's pullout from the ACA a big problem? Brookings' Aaron says no: brookings.edu/blogs/health36…. I made the same pt.: latimes.com/business/hiltz…

Sorry, parents: Genetic tests won't show if your kid will be a sports superstar

latimes.com — The business of selling genetic tests to parents hoping to determine if their kids are fated to become sports stars has just sustained a couple of body blows from scientific papers published in two international journals. Their mutual conclusion is that genetic testing can't tell us anything about...
Nov 19, 2015

Sorry, parents: Genetic tests won't show if your kid will be a sports superstar lat.ms/1YirgXE

Healthcare shocker: Medicaid is very good for kids

latimes.com — Medicaid is the healthcare family's poor relation. Its quality is widely derided, even as it's typically saddled with the lowest provider reimbursement rates of any government health program. Republican governors and legislatures refused to accept the central role it was given as the insurance plan for their poorest constituents (though that's been changing).

Could Uber possibly be worth $70 billion? (We vote no.)

latimes.com — In the summer of 2014, after investors bestowed $1.2 billion on the ride-hailing service Uber, some economic commentators ridiculed its then-valuation of $17 billion. "Even smart investors can collectively make big mistakes, especially if they lose perspective," argued finance expert Aswath Damodaran of NYU's Stern School of Business.

Pfizer's creative merger plan revives concerns about tax-avoiding 'inversions'

latimes.com — A corporate tax dodge known as "inversions" had a moment in the spotlight about a year ago, when a number of such high-profile mergers got U.S. Treasury officials, politicians and voters steaming. Inversions are mergers in which a big U.S. company buys a smaller foreign company and reincorporates...
More Articles →
Dec 01, 2015

@davidtedu @EdwardTufte David, thanks for being so responsive..i tweeted the same point to Prof Tufte, who I also admire greatly..

Dec 01, 2015

You might want to take a closer look at the statistics cited in that piece, as I did: latimes.com/business/hiltz… twitter.com/davidtedu/stat…

Dec 01, 2015

You might want to take a closer look at the research cited in that piece, as I did: latimes.com/business/hiltz… twitter.com/edwardtufte/st…

Nov 30, 2015

Why that eye-catching stat about how no one reads academic papers is totally bogus: fw.to/eD68JLf

Nov 30, 2015

How that drug co. CEO who jacked up a drug price by 5,000% is roiling biotech--again fw.to/21JgMmP

Nov 30, 2015

How to use a study that was sorta true 30 years ago to make a bogus point about academia in 2015--so no one notices: fw.to/eD68JLf

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.